Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth
factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC) …

In recent years, the high heterogeneity of colorectal cancer (CRC) has become evident.
Hence, biomarkers need to be developed that enable the stratification of patients with CRC …

A main limitation of therapies that selectively target kinase signalling pathways is the
emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the …

The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic
colorectal cancers. Mutations in KRAS, NRAS, and BRAF and amplification of ERBB2 and …

KRAS (kirsten rat sarcoma viral oncogene) is a member of the RAS family. KRAS mutations
are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS …

Background. In metastatic colorectal cancer, mutation testing for KRAS exon 2 is widely
implemented to select patients with wild-type tumors for treatment with the monocloncal anti …

Despite the success of targeted therapies in the treatment of cancer, the development of
resistance limits the ability to translate this method into a curative treatment. The …

Large-scale DNA sequencing of cancer genomes has provided insight into the clonality of
tumor cells, in addition to potential targets for new therapeutic approaches. This review …

Colorectal tumors become more heterogeneous after progression on EGFR-inhibitors by
developing multiple independent mutations. Upon discontinuation of treatment, the mutant …

The KRAS oncogene is mutated in approximately 35%-45% of colorectal cancers, and
KRAS mutational status testing has been highlighted in recent years. The most frequent …